Safe and effective administration of BCG for bladder carcinoma in situ after umbilical cord blood stem cell transplantation.

Toshihiro MagaribuchiShusuke AkamatsuTakashi KobayashiHiroshi KawabataToshinari YamasakiTakahiro InoueOsamu Ogawa

Published in: Transplant infectious disease : an official journal of the Transplantation Society (2017)

Although intravesical Bacillus Calmette-Guérin (BCG) instillation is the standard treatment for carcinoma in situ of the bladder, it is generally contraindicated in immunocompromised patients. Here we report the first case, to our knowledge, of BCG treatment for a bladder cancer patient who had received umbilical cord blood stem cell transplantation (UCBSCT). BCG can be given safely and effectively in select cases where reconstitution of the immune system has been achieved at least 2 years after UCBSCT.

Keyphrases

stem cell transplantation
umbilical cord
mesenchymal stem cells
high dose
spinal cord injury
healthcare
newly diagnosed
ejection fraction
muscle invasive bladder cancer
low dose
intensive care unit
prognostic factors
acute respiratory distress syndrome